US Customer Places Upgrade Order for Two Nexstim NBS 6 Systems
July 01 2024 - 4:30AM
US Customer Places Upgrade Order for Two Nexstim NBS 6 Systems
Press release, Helsinki, 1 July 2024 at 11:30 AM
(EEST)
US Customer Places Upgrade Order for Two
Nexstim NBS 6 Systems
Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company")
announces that it has received an order and delivered two new NBS 6
systems to a private clinic customer in the United States. The
customer is an experienced Nexstim system user that is now
upgrading its existing systems at two clinic locations.
Nexstim launched NBS 6, a new generation nTMS
system, in 2023. The NBS 6 is cleared by the FDA for the treatment
of Major Depressive Disorder (MDD) in adult patients who have
failed to achieve satisfactory improvement from prior
antidepressant medication in the current episode.
Mikko Karvinen, CEO of Nexstim, comments: “Very
happy to announce this order from one of our most active therapy
users. Nexstim’s NBS 6 system brings the usability of our
state-of-the-art TMS technology to an even better level and allows
the delivery of effective treatments to MDD patients. We are
excited to see both new and experienced customers get well
acquainted with the new system generation resulting from our
focused research and development efforts.”
Further information is available on the
website www.nexstim.com, or by
contacting:
Mikko Karvinen, CEO +358 50 326
4101 mikko.karvinen@nexstim.com
About Nexstim Plc
Nexstim is a Finnish, globally operating
growth-oriented medical technology company. Our mission is to
enable personalized and effective diagnostics and therapies for
challenging brain diseases and disorders.
Nexstim has developed a world-leading
non-invasive brain stimulation technology for navigated
transcranial magnetic stimulation (nTMS) with highly sophisticated
3D navigation providing accurate and personalized targeting of the
TMS to the specific area of the brain.
Nexstim’s Diagnostics Business focuses on
commercialization of the Navigated Brain Stimulation (NBS) system.
The NBS System 5 is the only FDA cleared and CE marked navigated
TMS system for presurgical mapping of the speech and motor cortices
of the brain.
Nexstim’s Therapy Business markets and sells the
NBS System 6 which is FDA cleared for marketing and commercial
distribution for the treatment of major depressive disorder (MDD)
in the United States. In Europe, the NBS 6 system is CE marked for
the treatment of major depression and chronic neuropathic pain.
Nexstim shares are listed on Nasdaq First North
Growth Market Finland.
For more information, please visit
www.nexstim.com
- Nexstim Plc_Press release_US order_01072024_FINAL